Cambridge Healthtech Institute第2屆

Emerging Immuno-Oncology Targets

( 癌症免疫療法的新標的 )

癌症免疫療法與併用療法的新標的與途徑

2018年8月30日~31日

本單元以癌症免疫療法的新標的為主題,具有免疫調節功能的抑制劑及拮抗標的、間質細胞與免疫細胞標的、免疫療法的合理併用策略等各種與新標的相關的心議題將被提出,也將發表以發現及驗證癌症免疫療法新標的與併用療法為目的的臨床前研究與轉譯研究的個案發表。

Coverage will include, but is not limited to:

  • Emerging immunomodulatory targets
  • Checkpoint inhibitors (PD-1/PD-L1, CTLA-4, TIM3, LAG3)
  • Targeting agonist receptors (OX40, 4-1BB, GITR, CD27, ICOS, GITR)
  • Targeting tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs)
  • Targeting the STING pathway
  • Targeting CD96 and TIGIT for cancer immunotherapy
  • Targeting the stroma, tumor microenvironment
  • Targeting innate immunity
  • Rational combination immunotherapy

* 活動內容有可能不事先告知作更動及調整。

Choose your language
Chinese
Japanese
Korean
English





免費電子郵件通知服務